<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="194">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on December 16, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05158621</url>
  </required_header>
  <id_info>
    <org_study_id>GO-007</org_study_id>
    <nct_id>NCT05158621</nct_id>
  </id_info>
  <brief_title>A Screening Study Targeting Tumor-specific Antigens</brief_title>
  <official_title>A Screening Study for the Selection of Patients for Clinical Studies Targeting Tumor-specific Antigens</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Gritstone Oncology, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Gritstone Oncology, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to identify patients who may be eligible to participate in a&#xD;
      treatment protocol based on characteristics of their tumor. This may include the&#xD;
      manufacturing of a patient-specific vaccine, which involves neoantigen prediction and&#xD;
      generating a vaccine targeting neoantigens.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The screening study can enroll multiple tumor types in multiple treatment settings for the&#xD;
      potential inclusion in a treatment study. Patient's tumors are analyzed to determine if the&#xD;
      patient's tumor contains sufficient mutations. This screening study is currently enrolling&#xD;
      patients with localized colon cancer or metastatic colorectal cancer for the development of a&#xD;
      patient-specific neoantigen-based cancer vaccine that requires a manufacturing period for&#xD;
      each patient.&#xD;
&#xD;
      The process of generating a patient-specific neoantigen cancer vaccine involves multiple&#xD;
      steps, including collection of patient tumor and blood specimens, performing next-generation&#xD;
      sequencing (NGS), predicting the neoantigens to be included in the patient-specific vaccine,&#xD;
      and the manufacture and release of the patient-specific vaccine.&#xD;
&#xD;
      Study participants will not receive any investigational treatment as part of this trial.&#xD;
      Patients screened in this study may be able to enroll in a separate investigational treatment&#xD;
      study sponsored by Gritstone, provided that the patient meets the specified eligibility&#xD;
      criteria for that treatment study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 17, 2021</start_date>
  <completion_date type="Anticipated">July 2022</completion_date>
  <primary_completion_date type="Anticipated">May 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Primary</measure>
    <time_frame>at study enrollment</time_frame>
    <description>To identify patients with a defined tumor-specific profile (or tumor-specific characteristics, proteins, mutations) for potential inclusion in a separate clinical study that involves investigational study treatment.</description>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Metastatic Colorectal Cancer</condition>
  <condition>Stage II/III Colon Cancer</condition>
  <arm_group>
    <arm_group_label>Advanced/Metastatic Colorectal Cancer</arm_group_label>
    <description>Eligible patients include those with newly-diagnosed or recurrent advanced/metastatic CRC who are initiating fluoropyrimidine and oxaliplatin (FOLFOX or CAPEOX) in combination with bevacizumab. Patients will then be assessed to determine if sufficient neoantigens are identified using Gritstone's proprietary prediction algorithm, EDGE, to warrant manufacturing of a patient-specific vaccine. Patients with sufficient neoantigens will have vaccine manufactured while receiving FOLFOX or CAPEOX/bevacizumab.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Localized Colon Cancer</arm_group_label>
    <description>Eligible patients include those with high-risk Stage II or Stage III colon cancer who have MRD based on the presence of ctDNA following surgical resection. Patients with MRD will then be assessed to determine if sufficient neoantigens are identified using Gritstone's proprietary prediction algorithm, EDGE, to warrant manufacturing of a patient-specific vaccine.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>blood collection for research (next generation sequencing [NGS])</intervention_name>
    <description>participants will have whole blood collected for NGS</description>
    <arm_group_label>Advanced/Metastatic Colorectal Cancer</arm_group_label>
    <arm_group_label>Localized Colon Cancer</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>blood collection for research (HLA typing)</intervention_name>
    <description>participants will have whole blood collected for HLA typing</description>
    <arm_group_label>Advanced/Metastatic Colorectal Cancer</arm_group_label>
    <arm_group_label>Localized Colon Cancer</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>blood collection for research (circulating tumor DNA [ctDNA])</intervention_name>
    <description>participants will have whole blood collected for ctDNA detection</description>
    <arm_group_label>Localized Colon Cancer</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Newly-diagnosed or recurrent advanced/metastatic CRC who are initiating fluoropyrimidine&#xD;
        and oxaliplatin (FOLFOX or CAPEOX) in combination with bevacizumab. Patients will then be&#xD;
        assessed to determine if sufficient neoantigens are identified using Gritstone's&#xD;
        proprietary prediction algorithm, EDGE, to warrant manufacturing of a patient-specific&#xD;
        vaccine.&#xD;
&#xD;
        High-risk Stage II or Stage III colon cancer who have MRD based on the presence of ctDNA&#xD;
        following surgical resection. Patients with MRD will then be assessed to determine if&#xD;
        sufficient neoantigens are identified using Gritstone's proprietary prediction algorithm,&#xD;
        EDGE, to warrant manufacturing of a patient-specific vaccine.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        ADVANCED/METASTATIC COLORECTAL CANCER&#xD;
&#xD;
        Inclusion Criteria:&#xD;
&#xD;
          -  signed and dated ICF prior to initiation of study-specific procedures&#xD;
&#xD;
          -  histologically confirmed metastatic CRC who are planned for or who have received no&#xD;
             more than one cycle of first-line treatment in the advanced/metastatic setting with a&#xD;
             fluoropyrimidine and oxaliplatin in combination with bevacizumab&#xD;
&#xD;
          -  measurable and unresectable disease according to RECIST v1.1&#xD;
&#xD;
          -  known KRAS status&#xD;
&#xD;
          -  availability of FFPE tumor specimens from biopsy within the previous 12 months for&#xD;
             sequencing and neoantigen prediction&#xD;
&#xD;
          -  ≥ 12 years of age&#xD;
&#xD;
          -  ECOG performance status of 0 or 1 or equivalent for patients of 12-17 years of age&#xD;
&#xD;
          -  adequate organ function (further defined in protocol)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  known microsatellite instability (MSI)hi disease based on institutional standard&#xD;
&#xD;
          -  known tumor mutation burden &lt;1 nonsynonymous mutations/MB&#xD;
&#xD;
          -  patients with BRAF V600E mutations&#xD;
&#xD;
        LOCALIZED COLON CANCER&#xD;
&#xD;
        Inclusion Criteria:&#xD;
&#xD;
          -  signed and dated ICF prior to initiation of study-specific procedures&#xD;
&#xD;
          -  high-risk stage II or stage III colon cancer planned for or have completed surgical&#xD;
             resection and have not initiated or received more than 4 weeks of adjuvant&#xD;
             chemotherapy and be known ctDNA-positive via the Signatera assay&#xD;
&#xD;
          -  availability of FFPE tumor specimens for sequencing, determination of mutations for&#xD;
             detecting and monitoring ctDNA to identify patients with minimal residual disease, and&#xD;
             neoantigen prediction&#xD;
&#xD;
          -  ≥ 12 years of age&#xD;
&#xD;
          -  ECOG performance status of 0 or 1 or equivalent for patients of 12-17 years of age&#xD;
&#xD;
          -  adequate organ function (further defined in protocol)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  known microsatellite instability (MSI)hi disease based on institutional standard&#xD;
&#xD;
          -  known tumor mutation burden &lt;1 nonsynonymous mutations/MB&#xD;
&#xD;
        Complete list of inclusion and exclusion criteria are listed in the clinical study protocol&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Andy Ferguson</last_name>
    <phone>857-327-9816</phone>
    <email>aferguson@gritstone.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>UCLA</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Rachel Andes</last_name>
      <phone>310-794-6500</phone>
      <email>RAndes@mednet.ucla.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Miami Cancer Institute</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33176</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Antonio Ucar</last_name>
      <phone>786-596-2000</phone>
      <email>AntoniU@Baptisthealth.net</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Advanced Research</name>
      <address>
        <city>Tamarac</city>
        <state>Florida</state>
        <zip>33321</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Nilay Mehta</last_name>
      <phone>954-204-0052</phone>
      <email>nmehta@advancedresearchfl.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Astera Cancer Care</name>
      <address>
        <city>East Brunswick</city>
        <state>New Jersey</state>
        <zip>08816</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Percy Yeung</last_name>
      <phone>732-390-7750</phone>
      <phone_ext>3378</phone_ext>
      <email>Percy.Yeung@asterahealthcare.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>The Christ Hospital</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45219</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Abby Reed</last_name>
      <phone>513-585-3443</phone>
      <email>Abby.Reed@thechristhospital.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Sarah Cannon</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37203</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <email>cann.researchreferrals@scresearch.net</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Virginia Cancer Specialists</name>
      <address>
        <city>Fairfax</city>
        <state>Virginia</state>
        <zip>22031</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Carrie Friedman</last_name>
      <email>Carrie.Friedman@usoncology.com</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2021</verification_date>
  <study_first_submitted>December 2, 2021</study_first_submitted>
  <study_first_submitted_qc>December 2, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">December 15, 2021</study_first_posted>
  <last_update_submitted>December 2, 2021</last_update_submitted>
  <last_update_submitted_qc>December 2, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">December 15, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>personalized neoantigen cancer vaccine</keyword>
  <keyword>neoantigen cancer vaccine</keyword>
  <keyword>patient-specific immunotherapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colorectal Neoplasms</mesh_term>
    <mesh_term>Colonic Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

